Citius Pharmaceuticals (NASDAQ:CTXR) Shares Gap Down – What’s Next?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) gapped down before the market opened on Wednesday . The stock had previously closed at $4.15, but opened at $3.60. Citius Pharmaceuticals shares last traded at $3.61, with a volume of 360,299 shares trading hands.

Analyst Upgrades and Downgrades

CTXR has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th. D. Boral Capital reaffirmed a “hold” rating on shares of Citius Pharmaceuticals in a research note on Friday, November 22nd.

Citius Pharmaceuticals Stock Down 13.3 %

The stock has a market capitalization of $650.61 million, a price-to-earnings ratio of -15.22 and a beta of 1.66. The company’s 50-day simple moving average is $9.53 and its 200 day simple moving average is $14.27.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd bought a new position in shares of Citius Pharmaceuticals in the second quarter valued at approximately $29,000. XTX Topco Ltd acquired a new stake in Citius Pharmaceuticals during the 3rd quarter worth $47,000. Virtu Financial LLC acquired a new position in shares of Citius Pharmaceuticals in the 3rd quarter valued at $50,000. Miller Investment Management LP grew its holdings in shares of Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after buying an additional 49,640 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at $69,000. Institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.